Overall rank by patents
#10,852
of 50,000 tracked assignees
USPTO PatentsView assignee record - 28 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ).
The verdict
According to USPTO PatentsView, Apothecary ranks #10,852 of 50,000 tracked US assignees by granted-patent volume, with 28 patents across 8 technology areas.
Apothecary Products, Llc has been granted 28 US utility patents between 2015 and 2025, placing Apothecary Products, Llc at #10,852 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 4.8 claims per patent with primary concentration in A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ). As a US Corporation, Apothecary Products, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Apothecary sits between Amer Sports Digital Services Oy (28 patents, rank #10,853) and Atlas Copco IAS UK Limited (28 patents, rank #10,861) - the closest US assignees by grant volume. The composite Innovation Score of 44.5/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 9 grants, compared with 12 in the 2015–2019 window, a -25% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Apothecary Products, Llc's 4.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 8 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Amer Sports Digital Services Oy
28 patents
Americorp Investments LLC
28 patents
Amphenol Commercial Products (Chengdu) Co., Ltd.
28 patents
Anapass Inc.
28 patents
Aptinyx Inc.
28 patents
Ariad Pharmaceuticals, Inc.
28 patents
Aspen Technology, Inc.
28 patents
Atlas Copco IAS UK Limited
28 patents
Apothecary Products, LLC
28 patents
What this shows Apothecary holds 28 patents at rank #10,857, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #10,857 in granted patent volume.
Other assignees with the most granted patents in Apothecary's primary technology class.
Apothecary's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
45 Top 25% higher than 75% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 5 | 17.9% |
| 2016 | 1 | 3.6% |
| 2017 | 4 | 14.3% |
| 2018 | 2 | 7.1% |
| 2020 | 1 | 3.6% |
| 2021 | 1 | 3.6% |
| 2023 | 3 | 10.7% |
| 2024 | 4 | 14.3% |
| 2025partial year | 7 | 25.0% |
Top 8 of 8 technology areas
Historical grant data only; it does not rate legal strength or current strategy.
Overall rank by patents
#10,852
of 50,000 tracked assignees
44.5 out of 100
How to use this portfolio
Apothecary's 28 grants land it in the top 25% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.